Biopharma & Life Sciences
Spruce Biosciences Executive Compensation (FY25)
SPRB · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Javier Szwarcberg | Latest say-on-pay support = May 21, 2026 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Spruce Biosciences
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of October 27, 2026Latest filing (8-K): May 26, 2026
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
131 figures on this page: 129 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
More on Spruce Biosciences
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Javier Szwarcberg: $1,532,187 → $2,910,573 (90.0% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Spruce Biosciences' chief executive and what were they paid?
Javier Szwarcberg, Chief Executive Officer, received $2,910,573 in total compensation for fiscal 2025. Compared with the $1,532,187 reported for fiscal 2024, Szwarcberg's total was 90.0% higher.
What was Spruce Biosciences' say-on-pay result?
The say-on-pay proposal drew 62.7% of votes cast for or against in favor at the meeting held May 21, 2026 for fiscal 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Javier Szwarcberg Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Samir Gharib President and Chief Financial Officer (5) | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Ralph III Chief Medical Officer (6) | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Javier Szwarcberg Chief Executive Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Samir Gharib President and Chief Financial Officer (5) | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Ralph III Chief Medical Officer (6) | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Javier Szwarcberg Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Samir Gharib President and Chief Financial Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Javier Szwarcberg Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Samir Gharib President and Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Kirk Ways Interim Chief Medical Officer Served on an interim basis | — | — | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Javier Szwarcberg | RSU | ◇ | — | — | ◇ | — | — | — |
| Javier Szwarcberg MPH | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Javier Szwarcberg MPH | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Kirk Ways | RSU | ◇ | — | — | ◇ | — | — | — |
| Samir Gharib | RSU | ◇ | — | — | ◇ | — | — | — |
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Javier Szwarcberg | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Samir Gharib | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Kirk Ways | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 7/22/2035 | |
| RSU | ◇ | = | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Keli Walbert | ◇ | — | ◇ | — | — | — | ◇ |
Michael Grey Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Daniel Spiegelman | ◇ | — | ◇ | — | — | — | ◇ |
Camilla V. Simpson, M.Sc | ◇ | — | ◇ | — | — | — | ◇ |
Percival Barretto-Ko | ◇ | — | ◇ | — | — | — | ◇ |
Tiba Aynechi | ◇ | — | ◇ | — | — | — | ◇ |
Bali Muralidhar, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Javier Szwarcberg, M.D., MPH and Kirk Ways, M.D., Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 21, 2026 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Javier Szwarcberg (Chief Executive Officer), FY2025 total compensation $2,910,573 (base salary $610,000) [exec_comp, SEC accession 0001193125-26-149821, filed 2026-04-09]What this page does not include
Everything above is a fact Spruce Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Spruce Biosciences recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
131 figures on this page: 129 cited to the filing that reported them, 2 calculated from figures it prints.
129 cited to the filing
2 calculated from the filing
Documents cited
- 0001193125-26-239230Item 5.07 Submission of Matters to a Vote of Security Holders.
- 0001193125-26-149821Director Compensation
- 0000950170-24-042270
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Spruce Biosciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/SPRB (accessed 2026).
Short form: data: Velarion
The paid brief for Spruce Biosciences
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Spruce Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}